Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

However in 2020, she received a life-changing cystic fibrosis drug called Kaftrio, which transformed her life and drastically ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a ...

(RTTNews) - Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved a label expansion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

"We are pleased that the European Commission has broadened the KAFTRIO indication to include all CF patients 2 years and older who have at least one non-class I mutation, ensuring that even more ...

Listed below are the charts and positions for Trikafta/Kaftrio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Trikafta/Kaftrio. GlobalData provides trusted ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

However in 2020, she received a life-changing cystic fibrosis drug called Kaftrio, which transformed her life and drastically improved her health. Since then she has returned to full-time work, is in ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...